BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide
April 20, 2016 at 11:11 AM EDT
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares rose 4.7 percent after the company reported the findings from the Phase 2 trial ...